Industry Payments to Cardiologists

Amarnath Annapureddy¹, Karthik Murugiah^{1

2}, Karl E Minges^{1

2}, Philip W Chui², Nihar Desai^{1

2}, Jeptha P Curtis^{1

2}

Affiliations

¹ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, CT (A.A., K.M., K.E.M., N.D., J.P.C.).
² Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (K.E.M., K.M., P.W.C., N.D., J.P.C.).

Amarnath Annapureddy et al. Circ Cardiovasc Qual Outcomes. 2018 Dec.

. 2018 Dec;11(12):e005016.

doi: 10.1161/CIRCOUTCOMES.118.005016.

Amarnath Annapureddy¹, Karthik Murugiah^{1

2}, Karl E Minges^{1

2}, Philip W Chui², Nihar Desai^{1

2}, Jeptha P Curtis^{1

2}

¹ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, CT (A.A., K.M., K.E.M., N.D., J.P.C.).
² Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (K.E.M., K.M., P.W.C., N.D., J.P.C.).

No abstract available

Keywords: cardiologists; conflict of interest; drug industry; medical ethics; patient care.

MeSH terms